Vertex Pharmaceuticals Inc

VRTX

394.530USD

-3.040-0.77%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

25 / 176

Overall Ranking

127 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 32 analysts

Buy

Current Rating

480.698

Target Price

+21.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 23.40% year-on-year.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 535.60M.%!(EXTRA int=2)

Overvalued

The company’s latest PE is 27.93, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 252.71M shares, increasing 0.97% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 23.86M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.81.

The company's current financial score is 6.91, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 2.77B, representing a year-over-year increase of 2.96%, while its net profit experienced a year-over-year increase of 41.22%.

Score

Industry at a Glance

Previous score

6.91

Change

0



Financials

4.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.58

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.43

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.16

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 27.55, which is -2.62% below the recent high of 26.82 and 527.95% above the recent low of -117.88.

Score

Industry at a Glance

Previous score

4.25

Change

-0.04

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 25/176

No Data

The company’s current earnings forecast score is 7.35, which is lower than the Pharmaceuticals industry's average of 7.96. The average price target for Vertex Pharmaceuticals Inc is 485.00, with a high of 624.00 and a low of 330.00.

Score

Industry at a Glance

Previous score

7.44

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 7.10, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 454.13 and the support level at 343.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.55

Change

0.48

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 98.56%, representing a quarter-over-quarter increase of 0.34%. The largest institutional shareholder is The Vanguard, holding a total of 23.86M shares, representing 9.31% of shares outstanding, with 3.28% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Capital World Investors

28.53M

+0.73%

The Vanguard Group, Inc.

Star Investors

23.38M

+1.00%

Capital Research Global Investors

14.54M

+39.38%

BlackRock Institutional Trust Company, N.A.

14.00M

-2.31%

State Street Global Advisors (US)

11.79M

-1.59%

Fidelity Management & Research Company LLC

7.62M

-16.32%

Jennison Associates LLC

5.06M

+17.25%

Geode Capital Management, L.L.C.

5.76M

+2.01%

Invesco Capital Management (QQQ Trust)

5.31M

-0.39%

Wellington Management Company, LLP

5.45M

-7.80%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.32, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.44. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Vertex Pharmaceuticals Inc

VRTX

6.79 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cardinal Health Inc

CAH

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.